• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

COVID-19 抗体疗法临床试验。

COVID-19 antibodies on trial.

机构信息

Senior Editor, Nature Biotechnology, .

出版信息

Nat Biotechnol. 2020 Nov;38(11):1242-1252. doi: 10.1038/s41587-020-0732-8.

DOI:10.1038/s41587-020-0732-8
PMID:33087898
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7576980/
Abstract

With the first readouts of trials of antibodies against COVID-19 appearing and others coming thick and fast, asked a group of experts to comment on the challenges and timelines for these products.

摘要

随着针对 COVID-19 的抗体试验的首批结果出炉，其他试验也陆续公布，我们请专家组对这些产品的挑战和时间线进行了点评。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b94/7576980/be959003a7be/41587_2020_732_Figi_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b94/7576980/08db04bb245b/41587_2020_732_Figa_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b94/7576980/49d82daf5a2c/41587_2020_732_Figb_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b94/7576980/498d800da625/41587_2020_732_Figc_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b94/7576980/39e41e34ed8e/41587_2020_732_Figd_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b94/7576980/736742b5af81/41587_2020_732_Fige_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b94/7576980/36a71bda50ee/41587_2020_732_Figf_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b94/7576980/9fad320eb50e/41587_2020_732_Figg_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b94/7576980/b8bf045e1b3e/41587_2020_732_Figh_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b94/7576980/be959003a7be/41587_2020_732_Figi_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b94/7576980/08db04bb245b/41587_2020_732_Figa_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b94/7576980/49d82daf5a2c/41587_2020_732_Figb_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b94/7576980/498d800da625/41587_2020_732_Figc_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b94/7576980/39e41e34ed8e/41587_2020_732_Figd_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b94/7576980/736742b5af81/41587_2020_732_Fige_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b94/7576980/36a71bda50ee/41587_2020_732_Figf_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b94/7576980/9fad320eb50e/41587_2020_732_Figg_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b94/7576980/b8bf045e1b3e/41587_2020_732_Figh_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b94/7576980/be959003a7be/41587_2020_732_Figi_HTML.jpg

相似文献

1
COVID-19 antibodies on trial.COVID-19 抗体疗法临床试验。
Nat Biotechnol. 2020 Nov;38(11):1242-1252. doi: 10.1038/s41587-020-0732-8.
2
Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment.2019冠状病毒病（COVID-19）与免疫参与性癌症治疗
JAMA Oncol. 2020 Oct 1;6(10):1529-1530. doi: 10.1001/jamaoncol.2020.2367.
3
[COVID-19- what have we learned and where are we heading?].[新冠疫情——我们学到了什么，又将走向何方？]
Laeknabladid. 2020 Oct;106(10):449. doi: 10.17992/lbl.2020.10.598.
4
Convalescent serum therapy for COVID-19: A 19th century remedy for a 21st century disease.新冠康复者血清疗法：一种治疗21世纪疾病的19世纪疗法。
PLoS Pathog. 2020 Aug 12;16(8):e1008735. doi: 10.1371/journal.ppat.1008735. eCollection 2020 Aug.
5
COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies.新型冠状病毒肺炎：冠状病毒复制、发病机制及治疗策略
Cleve Clin J Med. 2020 Jun;87(6):321-327. doi: 10.3949/ccjm.87a.20047. Epub 2020 May 4.
6
Extracorporeal Hemoadsorption: An Option for COVID-19-Associated Cytokine Storm Syndrome.体外血液吸附：治疗新型冠状病毒肺炎相关细胞因子风暴综合征的一种选择
Shock. 2020 Nov;54(5):700-701. doi: 10.1097/SHK.0000000000001568.
7
Hypotension, Systemic Inflammatory Response Syndrome, and COVID-19: A Clinical Conundrum.低血压、全身炎症反应综合征与新型冠状病毒肺炎：一个临床难题。
Anesth Analg. 2020 Sep;131(3):e175-e176. doi: 10.1213/ANE.0000000000005062.
8
COVID-19 in a Kidney Transplant Patient.一名肾移植患者的新型冠状病毒肺炎
Eur Urol. 2020 Jun;77(6):769-770. doi: 10.1016/j.eururo.2020.03.036. Epub 2020 Apr 6.
9
COVID-19 convalescent plasma: phase 2.COVID-19 恢复期血浆：第 2 阶段。
Transfusion. 2020 Jun;60(6):1332-1333. doi: 10.1111/trf.15842. Epub 2020 May 12.
10
Active Therapy with Passive Immunotherapy May Be Effective in the Fight against COVID-19.主动疗法联合被动免疫疗法可能对对抗新冠病毒有效。
Clin Transl Sci. 2020 Sep;13(5):835-837. doi: 10.1111/cts.12816. Epub 2020 Jun 26.

引用本文的文献

1
Rhinovirus, an Age-Old Problem Yet to be Solved: A Comprehensive Review Discussing Modern Therapeutics.鼻病毒，一个尚未解决的古老问题：一篇讨论现代疗法的综述
Health Sci Rep. 2025 Aug 6;8(8):e70922. doi: 10.1002/hsr2.70922. eCollection 2025 Aug.
2
Exploring the standardized detection and sampling methods of human nasal SARS-CoV-2 RBD IgA.探索人鼻SARS-CoV-2 RBD IgA的标准化检测和采样方法。
Front Immunol. 2025 May 20;16:1571418. doi: 10.3389/fimmu.2025.1571418. eCollection 2025.
3
Comprehensive analysis of nasal IgA antibodies induced by intranasal administration of the SARS-CoV-2 spike protein.

本文引用的文献

1
Distinct Early Serological Signatures Track with SARS-CoV-2 Survival.与 SARS-CoV-2 存活相关的早期血清学特征。
Immunity. 2020 Sep 15;53(3):524-532.e4. doi: 10.1016/j.immuni.2020.07.020. Epub 2020 Jul 30.
2
Potently neutralizing and protective human antibodies against SARS-CoV-2.强效中和和保护 SARS-CoV-2 的人源抗体。
Nature. 2020 Aug;584(7821):443-449. doi: 10.1038/s41586-020-2548-6. Epub 2020 Jul 15.
3
A perspective on potential antibody-dependent enhancement of SARS-CoV-2.对 SARS-CoV-2 潜在抗体依赖性增强作用的看法。
对经鼻内给予严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白所诱导的鼻腔免疫球蛋白A（IgA）抗体的综合分析。
Elife. 2025 May 8;12:RP88387. doi: 10.7554/eLife.88387.
4
Monoclonal antibodies: From magic bullet to precision weapon.单克隆抗体：从“魔弹”到“精准武器”。
Mol Biomed. 2024 Oct 11;5(1):47. doi: 10.1186/s43556-024-00210-1.
5
Short-term effectiveness of single-dose intranasal spray COVID-19 vaccine against symptomatic SARS-CoV-2 Omicron infection in healthcare workers: a prospective cohort study.单剂量鼻内喷雾式新冠疫苗对医护人员有症状的新冠病毒奥密克戎感染的短期有效性：一项前瞻性队列研究。
EClinicalMedicine. 2023 Dec 13;67:102374. doi: 10.1016/j.eclinm.2023.102374. eCollection 2024 Jan.
6
Passive antibody therapy in emerging infectious diseases.新发传染病中的被动抗体疗法。
Front Med. 2023 Dec;17(6):1117-1134. doi: 10.1007/s11684-023-1021-y. Epub 2023 Dec 2.
7
Adapting Neutralizing Antibodies to Viral Variants by Structure-Guided Affinity Maturation Using Phage Display Technology.利用噬菌体展示技术通过结构导向的亲和力成熟使中和抗体适应病毒变体
Glob Chall. 2023 Aug 21;7(10):2300088. doi: 10.1002/gch2.202300088. eCollection 2023 Oct.
8
An IgM-like inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2 variants.一种 IgM 样可吸入 ACE2 融合蛋白广泛中和 SARS-CoV-2 变体。
Nat Commun. 2023 Aug 25;14(1):5191. doi: 10.1038/s41467-023-40933-3.
9
Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters.鼻腔内接种流感病毒载体 COVID-19 疫苗可抑制仓鼠的 SARS-CoV-2 炎症反应。
Nat Commun. 2023 Jul 11;14(1):4117. doi: 10.1038/s41467-023-39560-9.
10
A neutralizing bispecific single-chain antibody against SARS-CoV-2 Omicron variant produced based on CR3022.基于 CR3022 产生的针对 SARS-CoV-2 奥密克戎变异株的中和双特异性单链抗体
Front Cell Infect Microbiol. 2023 May 3;13:1155293. doi: 10.3389/fcimb.2023.1155293. eCollection 2023.
Nature. 2020 Aug;584(7821):353-363. doi: 10.1038/s41586-020-2538-8. Epub 2020 Jul 13.
4
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.在小动物模型中分离出有效的 SARS-CoV-2 中和抗体并预防疾病。
Science. 2020 Aug 21;369(6506):956-963. doi: 10.1126/science.abc7520. Epub 2020 Jun 15.
5
Dissecting antibody-mediated protection against SARS-CoV-2.解析针对 SARS-CoV-2 的抗体介导保护作用。
Nat Rev Immunol. 2020 Jul;20(7):392-394. doi: 10.1038/s41577-020-0359-5. Epub 2020 Jun 8.
6
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.人类单克隆 SARS-CoV 抗体对 SARS-CoV-2 的交叉中和作用。
Nature. 2020 Jul;583(7815):290-295. doi: 10.1038/s41586-020-2349-y. Epub 2020 May 18.
7
SARS-CoV-2 productively infects human gut enterocytes.SARS-CoV-2 能有效地感染人类肠道肠细胞。
Science. 2020 Jul 3;369(6499):50-54. doi: 10.1126/science.abc1669. Epub 2020 May 1.
8
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.埃博拉病毒病治疗的随机、对照试验。
N Engl J Med. 2019 Dec 12;381(24):2293-2303. doi: 10.1056/NEJMoa1910993. Epub 2019 Nov 27.
9
A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection.一种包裹脂质的 mRNA 编码了一种强效中和的人源单克隆抗体，可预防基孔肯雅热感染。
Sci Immunol. 2019 May 17;4(35). doi: 10.1126/sciimmunol.aaw6647.
10
Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection.工程化 mRNA 表达的抗体可预防呼吸道合胞病毒感染。
Nat Commun. 2018 Oct 1;9(1):3999. doi: 10.1038/s41467-018-06508-3.